Screening

On 30 September 2026, Italy published two decrees updating the national Essential Levels of Care (Livelli Essenziali di Assistenza, LEA). The changes combine an approximately €149.5 million expansion of nationally covered services, including new screening programmes, IVD tests and prosthetic aids, with resource-neutral revisions to existing coding, nomenclature and prescribing requirements. Together, the measures expand coverage for selected technologies while updating the conditions governing access to existing services.

On September 23, 2026, the National Cancer Strategy Roadmap was released in Finland. It describes the measures, responsibilities, schedules, and conditions for implementing the strategy in practice during the first five-year period (2026-2031). The objectives are to develop person-centered services, reduce the cancer burden through prevention and early detection, and ensure effective and equitable care. Overall, implementation of the National Cancer Strategy is estimated to require approximately €140 million in additional investment.

In September 2026, the Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) is working on 23 projects, including several Med Tech-related assessments concerning the diagnosis of endometriosis, newborn screening, and allergy diagnostic tests.

In June 2026, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned newborn screening for severe combined immunodeficiency, primary endovascular revascularization procedures for chronic limb-threatening ischemia, placental growth factor (PLGF)-based testing for suspected pre-eclampsia, and digital front door technologies before assessment for NHS Talking Therapies.

The UK National Screening Committee (UK NSC) will launch the 2026 open call for topics on July 1. Proposals may be submitted until September 30, 2026. The UK NSC conducts calls for topics every two years. Proposals may relate to new screening topics, updates to previously considered topics, or changes to existing screening programmes.

On June 9, 2026, the Swiss Federal Office of Public Health published changes to the Healthcare Benefit Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The nearest changes will take effect on July 1, 2026, and include the introduction of the first-trimester preeclampsia screening and adjustment of the tariffs for the highest-grossing laboratory analyses (Annex 3 KLV), changes in reimbursement conditions for medical aids via the List of Medical Aids MiGel (Annex 2 KLV), as well as the expansion of the outpatient-before-inpatient policy (Annex 1a KLV) and update of coverage decisions on the List of explicitly evaluated services (Annex 1 KLV).

On April 20, 2026, the Common Package of Benefits of the Spanish National Health System was amended (by Order SND/356/2026, of April 13, 2026). The key changes relate to diagnostic imaging, in-vitro diagnostics, obstetrics and gynecology, and some other fields.

On April 9, 2026, the Spanish Network of HTA Agencies (RedETS) published the 2026 working plan for health technology assessments. The plan includes a wide range of topics in cardiovascular, dermatology, diagnostic imaging, e-health, endocrine, endoscopy, gastrointestinal, ICU/OR, in-vitro diagnostics, neurology and neurosurgery, neuromodulation, ophthalmology, radiology, robotic surgery, and some other fields.

In March 2026, the National Institute for Health and Care Research (NIHR) in England released five Med Tech-related assessments in its HTA Journal, which concerned eye screening programs in diabetes, surgical and non-surgical splint treatment for finger fractures, diagnostic strategies for ovarian cancer, biomarkers for outcomes prediction in adults with suspected sepsis, and diagnostic tools of peripheral arterial disease in diabetes.

On April 1, 2026, the revised EBM (German Uniform Evaluation Standard) catalog for the second quarter of 2026 came into force. The EBM catalog is used to reimburse day case and outpatient services under the fee-for-service model. The key changes include the introduction of new EBM codes for the reimbursement of lung cancer screening, monitoring progress, and evaluating the digital health application, as well as several IVD tests

In April 2026, the Canary Islands Healthcare Evaluation Service is working on several HTAs, including evaluations in e-health, IVD, neuromodulation, obstetrics and gynecology, and some other fields.

In March 2026, the Galician Agency for Health Technology Assessment (Avalia-t) is working on several HTAs, including in cardiovascular, dermatology, e-health, gastrointestinal, interventional radiology, robotic surgery, in-vitro diagnostics, peripheral vascular, neurology and neurosurgery, neuromodulation, and some other fields.